Compounded Mounjaro: What You're Really Buying, With 7 Providers Priced

7 compounded tirzepatide providers, one by one

None of these seven sells anything called "Mounjaro." They sell compounded tirzepatide. How clearly each one says so tells you something about it.

• Lowest price, no membership, no prepay: Eden, about $130 a month at every dose.
• Cheapest first month: Mochi Health, about $90. After that, about $170 a month at the lowest dose.
• Cheapest tablet instead of a shot: Curex, about $250 a month at the starting dose.
• Coaching and a dietitian: Fridays, about $240 a month on a prepaid year.
• Type 2 diabetes with insurance that covers Mounjaro: skip compounding. Lilly's savings card can bring the real drug to $25 a fill.

Mochi Health: our pick, with the cheapest first month

Since August 2026, Mochi prices tirzepatide by dose. The medicine costs about $90 a month at the lowest dose and about $200 at the top. A $79 monthly membership comes on top, so the total runs about $170 to $280.

New members get the first month of membership free, though not in every state. That makes the first month about $90. A prepaid year of membership brings the lowest dose to about $140 a month.

We pick Mochi because it pairs a low price with more than 400 board-certified providers. Its BBB profile is accredited, with an A rating.

Mochi now works as a pharmacy marketplace, so prices can vary by pharmacy. Lilly sued Mochi in 2025 over how it marketed compounded tirzepatide. In April 2026, a judge let Lilly's claims proceed. That is a dispute about advertising, not a finding about the medicine. See the Mochi Health review.

Eden: the lowest price, the same at every dose

Eden charges about $130 a month at every dose, all in. There is no membership and no prepay. That is the lowest price on this page.

Two cautions. In June 2026, the FDA sent Eden a warning letter. Its website showed vials labeled with Eden's name, although Eden had not made them. Eden also has an F rating with the BBB, with many unanswered complaints about billing and refunds. See the Eden review.

Curex: the cheapest tablet, if you read the fine print

Curex has no membership. Its price covers the online visit, the medicine and shipping. It sells tirzepatide as a weekly shot or as a tablet that dissolves under the tongue.

Its "from $199" headline is the price of a year paid upfront, at the lowest dose. Month to month, you pay more:

• Tablet: about $250 a month at the starting dose, about $350 at higher doses.
• Shot: about $300 a month at the starting dose, about $400 at higher doses.
• A year paid upfront: from about $200 a month, or about $2,390 at once.

Curex says plainly that Mounjaro and Zepbound are Lilly's brands and that it is not affiliated with Lilly. That is the honest labeling to look for. It does not serve Arkansas, Connecticut, Hawaii, Massachusetts, Missouri or New Mexico. In California, it offers only the tablet.

Peak Wellness: watch the plan length

Peak Wellness charges the same price at every dose, with no membership. The plan length sets the price:

• Month to month: about $350 a month, after a first month of about $280.
• 3-month plan: about $280 a month, or about $840 at once.
• 6-month plan: about $230 a month, or about $1,400 at once.

There is no yearly plan.

Fridays: coaching and a dietitian included

Fridays sells tirzepatide as a program. Visits, a dietitian, group coaching and an app are included. It costs about $390 a month with no commitment, or about $240 a month on a year paid upfront.

If you would pay for coaching anyway, the prepaid year reads better than it first looks. But a year paid upfront is hard to get back if you need to stop. Its BBB profile also shows many unanswered complaints about refunds. See the Fridays review.

Willow: priced by dose, in 36 states

Willow sends one monthly bill, with visits and shipping included and no membership. The shot costs about $400 a month at the starting doses. It rises to about $550 at the top dose, the highest price on this page.

Willow also sells a tablet that dissolves under the tongue, for about $400 to $460 a month. It serves 36 states, so check yours before the intake. Lilly's 2025 lawsuit against Willow was dismissed in February 2026, and Lilly has appealed. See the Willow review.

Henry Meds: tablets only, three months at a time

Henry Meds sells compounded tirzepatide only as a tablet. It no longer lists a tirzepatide shot. The tablet costs about $350 a month, sold as a 3-month supply. Paid in full, it comes to about $300 a month.

Visits, supplies and shipping are included, with no membership fee. Henry Meds is also fighting a 2025 Eli Lilly lawsuit over its advertising. See the Henry Meds review.

Can you actually buy "compounded Mounjaro"?

No, not under that name. Mounjaro is Eli Lilly's FDA-approved brand of tirzepatide. A pharmacy cannot copy that finished product and sell it under Lilly's brand.

What a licensed pharmacy can do is compound tirzepatide itself, under its generic name, for one patient. So an ad for "compounded Mounjaro" sells compounded tirzepatide under a name it has no right to.

Lilly has fought over the name more than once. In September 2023, it sued six medical spas and wellness centers in Arizona, Florida, Georgia, Minnesota, South Carolina and Utah. Lilly said they sold their own tirzepatide as "Mounjaro" for weight loss.

One case, against Totality Medispa in Charleston, settled in May 2024. The spa agreed to stop using Lilly's branding. It also agreed to say its product is not FDA-approved.

In April 2025, Lilly sued four telehealth companies: Mochi Health, Willow, Henry Meds and Fella Health. Lilly said their ads called compounded tirzepatide "personalized" while trading on Lilly's brands.

If a provider sells "compounded Mounjaro" instead of "compounded tirzepatide," treat it as a signal about the provider. It is not just a word choice.

Is compounded tirzepatide still legal in 2026?

Yes, but on narrower ground than during the shortage. The FDA declared the tirzepatide shortage over in December 2024.

Pharmacies then had to stop making shortage-era copies. Smaller 503A pharmacies, which compound for one patient at a time, had until February 18, 2025. Larger 503B outsourcing facilities, which can make big batches, had until March 19, 2025.

What remains is the 503A path. A state-licensed pharmacy can make tirzepatide for a named patient, on a prescription. The FDA says compounded drugs should be used only when an approved drug does not meet a patient's medical need. An allergy to an ingredient in the approved drug is one example. A lower price is not a medical need.

On April 30, 2026, the FDA proposed not adding tirzepatide to the list of bulk drugs that 503B facilities may compound from. The comment period, extended to July 30, 2026, has closed. There is no final decision yet. The proposal does not change the 503A rules.

Enforcement is rising too. In March 2026, the FDA sent 30 warning letters to telehealth companies over misleading claims about compounded GLP-1s.

How to find a legitimate compounding pharmacy for tirzepatide

Searching "Mounjaro compounding pharmacy near me" mostly brings up telehealth sign-up pages, not a store you can walk into. Most compounded tirzepatide now goes through telehealth.

You fill in an online intake, and a licensed clinician reviews it. A partner pharmacy, often in another state, then ships the medicine to you.

Some local compounding pharmacies will also fill a tirzepatide prescription from your own doctor. Either way, a few questions separate a real program from one cutting corners:

• Which pharmacy fills it? A legitimate program names the licensed pharmacy, not just its own brand.
• Is it accredited? PCAB accreditation, a quality seal for compounding pharmacies, is a good sign. So is a clean record with the state pharmacy board. Neither is required.
• Is there a real clinical review? A person should review your health history, and labs if needed. A quiz anyone passes is not enough.
• What is the product called? It should say "compounded tirzepatide," not "compounded Mounjaro."
• Is a prescription required? A site selling tirzepatide without a clinician's review is not operating legally.

Compounded tirzepatide vs. Mounjaro vs. Zepbound: what's different?

All three contain tirzepatide. They differ in how they are regulated and what they are approved for.

• Approved use: Mounjaro is approved for type 2 diabetes, in adults and children 10 and older. Since August 2026, it is also approved to lower the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes and high heart risk. Zepbound, approved in 2023, is for weight management and for sleep apnea with obesity. Compounded tirzepatide has no approved use, because it is not an approved drug.
• Review: the FDA reviewed Mounjaro and Zepbound as finished drugs. That review covers how they are made and how consistent each dose is. Compounded tirzepatide is made under state pharmacy rules, with no FDA review of each batch.
• Forms: Mounjaro and Zepbound are weekly shots. Some compounded tirzepatide comes as a tablet or as drops, forms neither brand has.
• Insurance and savings cards: Mounjaro and Zepbound can be covered by insurance, and Lilly offers savings cards for both. Compounded tirzepatide is cash only.

Some compounded versions add vitamin B12 or L-carnitine. These add-ons have not been studied with tirzepatide. For the Zepbound side, see compounded Zepbound. For the wider market, see compounded tirzepatide.

What compounded tirzepatide costs vs. Mounjaro

Mounjaro's own price depends on your coverage:

• Insurance that covers Mounjaro, plus Lilly's savings card: as little as $25 a fill, even for a 3-month fill. See Mounjaro savings.
• Work insurance that won't cover it: the same card brings it to about $500 a month.
• No insurance: Lilly sells Mounjaro through LillyDirect for about $500 a month, at every dose.
• Medicare, for type 2 diabetes: your Part D drug plan's copay. Your yearly out-of-pocket drug costs stop at $2,100 in 2026. Lilly's savings card does not apply.
• List price, no discount: about $1,110 a month.

Zepbound, the same drug approved for weight loss, costs less from Lilly. It runs about $300 to $450 a month by dose, if you refill on time. The Mounjaro cost breakdown has every tier.

Compounded tirzepatide on this page runs from about $130 to about $550 a month. Most of it costs less than Mounjaro's self-pay price.

It is not always cheaper than Zepbound, though. Eden and Mochi cost less than Zepbound at every dose. Most others cost more than Zepbound's starting dose, about $300 a month, unless you prepay. Willow's top price is higher than Zepbound's highest one.

Over a year, counting 13 four-week fills for Lilly's products:

• Mounjaro with the savings card: about $325.
• Compounded tirzepatide: from about $1,550 at Eden, up to about $6,590 at Willow's top dose.
• Zepbound self-pay: about $5,090 staying at 5 mg, or about $5,640 at 7.5 mg and up.
• Mounjaro self-pay: about $6,490.
• Mounjaro at list price: about $14,460.

Lilly's savings cards and its Zepbound self-pay prices are set through December 31, 2026. The Zepbound KwikPen offer also stops at 11 fills a year.

Red flags when shopping for compounded tirzepatide online

Cheap tirzepatide has drawn real fraud, not just pushy marketing. Watch for these:

• "Compounded Mounjaro" as a product name. It misuses Lilly's trademark.
• A pharmacy name you can't check. The FDA has found fake compounded tirzepatide whose labels named pharmacies that don't exist, or that never made the product.
• "For research purposes" or "not for human consumption." The FDA has warned companies selling tirzepatide this way. These products are not medicine.
• No prescription or clinician review. A hard stop, whatever the price.
• Unusual payment requests. Venmo, Zelle, cash apps or crypto instead of a normal card payment.

Is compounded tirzepatide worth it for you?

It depends on why you want it. Mounjaro is approved for type 2 diabetes, and insulin resistance often rises through perimenopause. So some women reading this have a real diagnosis.

If you have type 2 diabetes and your insurance covers Mounjaro, the savings card beats every compounded price on this page. You would pay more for a drug without FDA review. Compounding only makes sense if coverage truly isn't there.

If your goal is weight management, Mounjaro was never approved for that. So the fair comparison is compounded tirzepatide against Zepbound, not against Mounjaro.

Medicare can't cover a drug used only for weight loss. But its $50 GLP-1 Bridge covers the Zepbound KwikPen for members who qualify.